Nordic Issuing

Ongoing case

Eurocine Vaccines AB

Back to all cases

Eurocine Vaccines AB

4 Oct - 18 Oct 2022Rights issue

Eurocine Vaccines is a pharmaceutical company. The company develops vaccines with its own technology platform Endocine™, which are later licensed to partners for further development and commercialization. The development takes place in collaboration with other companies in the industry. The Endocine™ technology platform can also be offered to other companies for development within specific indications. The head office is in Solna.

Read more on the company's website

The offer in summary

Record date : 29 September 2022

Subscription period: 4 October - 18 October 2022

Subscription rights: Anyone who were shareholder in the Company on the record date of September 29, 2022 has a preferential right to subscribe for shares in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) subscription right. Five (5) subscription rights entitle to subscribe for three (3) new shares.

Subscription price: SEK 0.75

The offer: 10 421 943 shares which corresponds to ca MSEK 7.8

Trade with subscription rights: 4 October - 13 October 2022

Marketplace : Spotlight Stock Market

Financial advisor: Sedermera Corporate Finance

Subscribe directly via Nordnet here

Subscribe directly via Avanza here


  Teaser Memorandum


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.